Theratechnologies Inc.

TH

CA88338H7040

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 01:29:59 18/07/2024 am IST			5-day change	1st Jan Change
2.09 ^CAD	-3.24%		+3.98%	-2.34%

10/07	Theratechnologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2024	CI
10/07	Transcript : Theratechnologies Inc., Q2 2024 Earnings Call, Jul 10, 2024

Theratechnologies Appoints Philippe Dubuc as Senior Vice President and Chief Financial Officer

February 25, 2016 at 02:52 am IST

Theratechnologies Inc. announced the hiring of Philippe Dubuc as Senior Vice President and Chief Financial Officer. Mr. Dubuc brings more than 25 years of experience in investment banking in the healthcare sector and in management. He started his career as a management
consultant at Groupe Secor. He then served as Managing Director, Investment Banking at National Bank Financial.

Latest news about Theratechnologies Inc.

Theratechnologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2024	10/07	CI
Transcript : Theratechnologies Inc., Q2 2024 Earnings Call, Jul 10, 2024	10/07
Theratechnologies Swings to Q2 Profit as Revenue Rises 25%; Confirms FY24 Guidance	10/07	MT
Theratechnologies Brief: Fiscal 2024 revenue guidance confirmed between US$87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 million	10/07	MT
Theratechnologies Brief: Positive net income of US$1 million realized with Adjusted EBITDA of $5.5 million For Q2	10/07	MT
Theratechnologies Brief: Q2 Revenue of US$22 million represents 25% growth year-over-year	10/07	MT
Theratechnologies Inc. Provides Earnings Guidance for the Year 2024	10/07	CI
North American Morning Briefing : Powell's Second Day of Remarks Awaited	10/07	DJ
Theratechnologies Up Near 5% In US After Hours On Data Related To Its Lead Investigational Peptide Drug Conjugate Candidate	24/05	MT
Theratechnologies Brief: Says Sudocetaxel Zendusortide ASCO 2024 Presentation "Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors"	24/05	MT
Theratechnologies Reports on its Annual Meeting of Shareholders	10/05	CI
Theratechnologies Inc. Announces Frank Holler as Chair of the Board of Directors	10/05	CI
Transcript : Theratechnologies Inc. - Shareholder/Analyst Call	09/05
Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision	10/04	MT
Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug	10/04	MT
Transcript : Theratechnologies Inc., Q1 2024 Earnings Call, Apr 10, 2024	10/04
Theratechnologies Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	10/04	CI
Theratechnologies Brief: Citing Acceleration of Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer with enrollment of next cohort of patients underway at higher dose level	10/04	MT
Theratechnologies Brief: FY2024 revenue guidance confirmed between US$87-$90 million and an Adjusted EBITDA in the range of $13-15 million	10/04	MT
Theratechnologies Brief: Q1 2024 consolidated revenue of US$16.2 Million; Says Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA	10/04	MT
Theratechnologies Inc. Re-Affirms Earnings Guidance for the Fiscal Year 2024	10/04	CI
North American Morning Briefing : Traders Await -2-	10/04	DJ
Theratechnologies Inc. Preclinical Data Presentation At AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology? Oncology Platform	09/04	CI
Theratechnologies Inc. Appoints Elina Tea to its Board of Directors and as Member of the Company's Audit Committee	05/04	CI
Theratechnologies To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform	28/03	MT

Chart Theratechnologies Inc.

Duration

Period

More charts

Company Profile

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

Sector

Pharmaceuticals

Calendar

09/10/2024 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Theratechnologies Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.09 CAD

Average target price

8 CAD

Spread / Average Target

+282.78%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
THERATECHNOLOGIES INC.	-2.34%	70.21M
CSL LIMITED	+8.54%	100B
SAMSUNG BIOLOGICS CO.,LTD.	+11.97%	43.89B
BIOGEN INC.	-11.76%	33.24B
UCB	+79.59%	29.36B
BIOMARIN PHARMACEUTICAL INC.	-12.20%	16.08B
INCYTE CORPORATION	+4.00%	14.68B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-1.90%	12.87B
ALTEOGEN INC.	+178.17%	10.55B
SWEDISH ORPHAN BIOVITRUM AB	+4.72%	8.83B

Biopharmaceuticals

Theratechnologies Inc.

Equities

TH

CA88338H7040

Pharmaceuticals

Theratechnologies Appoints Philippe Dubuc as Senior Vice President and Chief Financial Officer

EPS Revisions